ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) was initiated by the US government to rapidly develop and test vaccines and therapeutics against COVID-19 in 2020. The ACTIV Therapeutics-Clinical Working Group selected ACTIV trial teams and clinical networks to expeditiously develo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and translational science 2024, Vol.8 (1), p.e151, Article e151
Main Authors: Keshtkar-Jahromi, Maryam, Anstrom, Kevin J, Barkauskas, Christina, Brown, Samuel M, Daar, Eric S, Fischer, William, Gibbs, Kevin W, Higgs, Elizabeth S, Hughes, Michael D, Jagannathan, Prasanna, LaVange, Lisa, Lindsell, Christopher J, Nayak, Seema U, Paredes, Roger, Parmar, Mahesh, Peltan, Ithan D, Proschan, Michael, Shotwell, Matthew S, Vock, David M, Yokum, Tammy, Adam, Stacey J
Format: Article
Language:English
Subjects:
ACTIV
Antiviral drugs
clinical trial
Clinical trials
COVID-19
COVID-19 Therapeutic Platform Trials Lessons Learned
COVID-19 vaccines
design
Enrollments
Hospitalization
Hospitals
lessons
Mortality
Pandemics
Pathogenesis
Patient safety
Review
Severe acute respiratory syndrome coronavirus 2
Therapeutic targets
Thrombosis
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c362t-42a4c368249c950c74086c3418d3f4860f6cc16b755171c62e3f1e57464c51b53
container_end_page
container_issue 1
container_start_page e151
container_title Journal of clinical and translational science
container_volume 8
creator Keshtkar-Jahromi, Maryam
Anstrom, Kevin J
Barkauskas, Christina
Brown, Samuel M
Daar, Eric S
Fischer, William
Gibbs, Kevin W
Higgs, Elizabeth S
Hughes, Michael D
Jagannathan, Prasanna
LaVange, Lisa
Lindsell, Christopher J
Nayak, Seema U
Paredes, Roger
Parmar, Mahesh
Peltan, Ithan D
Proschan, Michael
Shotwell, Matthew S
Vock, David M
Yokum, Tammy
Adam, Stacey J
description Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) was initiated by the US government to rapidly develop and test vaccines and therapeutics against COVID-19 in 2020. The ACTIV Therapeutics-Clinical Working Group selected ACTIV trial teams and clinical networks to expeditiously develop and launch master protocols based on therapeutic targets and patient populations. The suite of clinical trials was designed to collectively inform therapeutic care for COVID-19 outpatient, inpatient, and intensive care populations globally. In this report, we highlight challenges, strategies, and solutions around clinical protocol development and regulatory approval to document our experience and propose plans for future similar healthcare emergencies.
doi_str_mv 10.1017/cts.2024.1
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7e2590f8d0ee49e1b99ef50a2cfc40d2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7e2590f8d0ee49e1b99ef50a2cfc40d2</doaj_id><sourcerecordid>3122645132</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-42a4c368249c950c74086c3418d3f4860f6cc16b755171c62e3f1e57464c51b53</originalsourceid><addsrcrecordid>eNpdkU1rGzEQhkVpaUKaS39AEfRSAnY1-lptLyWYfhgMuTi9Clk7u5HZlVxpXei_z26chqSnmdG8PHqll5D3wJbAoPrsx7LkjMslvCLnnKl6YbSG18_6M3JZyp4xBoZrLcRbciZqWZmqUudke73arn_RMQfXly90g6WkWGiPLkdsaIinFW2whC4-zHdIC45jiB1NLXWR4oC5wzjSg4sNDsG_I2_aCYeXj_WC3H7_tl39XGxufqxX15uFF5qPC8mdnDrDZe1rxXwlmdFeSDCNaKXRrNXeg95VSkEFXnMULaCqpJZewU6JC7I-cZvk9vaQw-DyX5tcsA8HKXfW5TH4Hm2FXNWsNQ1DlDXCrq6xVcxx33rJGj6xvp5Yh-NuwMZP78mufwF9uYnhznbpjwVQXDCY3Xx6JOT0-4hltEMoHvveRUzHYgVwrqUCMV_28T_pPh1znP5qUoGWRnI1A69OKp9TKRnbJzfA7By-ncK3c_gWJvGH5_6fpP-iFvdffqgm</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3116484255</pqid></control><display><type>article</type><title>ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic</title><source>Open Access: PubMed Central</source><source>Cambridge University Press</source><creator>Keshtkar-Jahromi, Maryam ; Anstrom, Kevin J ; Barkauskas, Christina ; Brown, Samuel M ; Daar, Eric S ; Fischer, William ; Gibbs, Kevin W ; Higgs, Elizabeth S ; Hughes, Michael D ; Jagannathan, Prasanna ; LaVange, Lisa ; Lindsell, Christopher J ; Nayak, Seema U ; Paredes, Roger ; Parmar, Mahesh ; Peltan, Ithan D ; Proschan, Michael ; Shotwell, Matthew S ; Vock, David M ; Yokum, Tammy ; Adam, Stacey J</creator><creatorcontrib>Keshtkar-Jahromi, Maryam ; Anstrom, Kevin J ; Barkauskas, Christina ; Brown, Samuel M ; Daar, Eric S ; Fischer, William ; Gibbs, Kevin W ; Higgs, Elizabeth S ; Hughes, Michael D ; Jagannathan, Prasanna ; LaVange, Lisa ; Lindsell, Christopher J ; Nayak, Seema U ; Paredes, Roger ; Parmar, Mahesh ; Peltan, Ithan D ; Proschan, Michael ; Shotwell, Matthew S ; Vock, David M ; Yokum, Tammy ; Adam, Stacey J</creatorcontrib><description>Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) was initiated by the US government to rapidly develop and test vaccines and therapeutics against COVID-19 in 2020. The ACTIV Therapeutics-Clinical Working Group selected ACTIV trial teams and clinical networks to expeditiously develop and launch master protocols based on therapeutic targets and patient populations. The suite of clinical trials was designed to collectively inform therapeutic care for COVID-19 outpatient, inpatient, and intensive care populations globally. In this report, we highlight challenges, strategies, and solutions around clinical protocol development and regulatory approval to document our experience and propose plans for future similar healthcare emergencies.</description><identifier>ISSN: 2059-8661</identifier><identifier>EISSN: 2059-8661</identifier><identifier>DOI: 10.1017/cts.2024.1</identifier><identifier>PMID: 39478775</identifier><language>eng</language><publisher>England: Cambridge University Press</publisher><subject>ACTIV ; Antiviral drugs ; clinical trial ; Clinical trials ; COVID-19 ; COVID-19 Therapeutic Platform Trials Lessons Learned ; COVID-19 vaccines ; design ; Enrollments ; Hospitalization ; Hospitals ; lessons ; Mortality ; Pandemics ; Pathogenesis ; Patient safety ; Review ; Severe acute respiratory syndrome coronavirus 2 ; Therapeutic targets ; Thrombosis ; Vaccines</subject><ispartof>Journal of clinical and translational science, 2024, Vol.8 (1), p.e151, Article e151</ispartof><rights>The Author(s) 2024.</rights><rights>The Author(s), 2024. Published by Cambridge University Press on behalf of Association for Clinical and Translational Science. This work is licensed under the Creative Commons Attribution License This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024 2024 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c362t-42a4c368249c950c74086c3418d3f4860f6cc16b755171c62e3f1e57464c51b53</cites><orcidid>0000-0002-4590-5175 ; 0000-0002-3297-2811</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523015/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523015/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39478775$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Keshtkar-Jahromi, Maryam</creatorcontrib><creatorcontrib>Anstrom, Kevin J</creatorcontrib><creatorcontrib>Barkauskas, Christina</creatorcontrib><creatorcontrib>Brown, Samuel M</creatorcontrib><creatorcontrib>Daar, Eric S</creatorcontrib><creatorcontrib>Fischer, William</creatorcontrib><creatorcontrib>Gibbs, Kevin W</creatorcontrib><creatorcontrib>Higgs, Elizabeth S</creatorcontrib><creatorcontrib>Hughes, Michael D</creatorcontrib><creatorcontrib>Jagannathan, Prasanna</creatorcontrib><creatorcontrib>LaVange, Lisa</creatorcontrib><creatorcontrib>Lindsell, Christopher J</creatorcontrib><creatorcontrib>Nayak, Seema U</creatorcontrib><creatorcontrib>Paredes, Roger</creatorcontrib><creatorcontrib>Parmar, Mahesh</creatorcontrib><creatorcontrib>Peltan, Ithan D</creatorcontrib><creatorcontrib>Proschan, Michael</creatorcontrib><creatorcontrib>Shotwell, Matthew S</creatorcontrib><creatorcontrib>Vock, David M</creatorcontrib><creatorcontrib>Yokum, Tammy</creatorcontrib><creatorcontrib>Adam, Stacey J</creatorcontrib><title>ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic</title><title>Journal of clinical and translational science</title><addtitle>J Clin Transl Sci</addtitle><description>Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) was initiated by the US government to rapidly develop and test vaccines and therapeutics against COVID-19 in 2020. The ACTIV Therapeutics-Clinical Working Group selected ACTIV trial teams and clinical networks to expeditiously develop and launch master protocols based on therapeutic targets and patient populations. The suite of clinical trials was designed to collectively inform therapeutic care for COVID-19 outpatient, inpatient, and intensive care populations globally. In this report, we highlight challenges, strategies, and solutions around clinical protocol development and regulatory approval to document our experience and propose plans for future similar healthcare emergencies.</description><subject>ACTIV</subject><subject>Antiviral drugs</subject><subject>clinical trial</subject><subject>Clinical trials</subject><subject>COVID-19</subject><subject>COVID-19 Therapeutic Platform Trials Lessons Learned</subject><subject>COVID-19 vaccines</subject><subject>design</subject><subject>Enrollments</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>lessons</subject><subject>Mortality</subject><subject>Pandemics</subject><subject>Pathogenesis</subject><subject>Patient safety</subject><subject>Review</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Therapeutic targets</subject><subject>Thrombosis</subject><subject>Vaccines</subject><issn>2059-8661</issn><issn>2059-8661</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpdkU1rGzEQhkVpaUKaS39AEfRSAnY1-lptLyWYfhgMuTi9Clk7u5HZlVxpXei_z26chqSnmdG8PHqll5D3wJbAoPrsx7LkjMslvCLnnKl6YbSG18_6M3JZyp4xBoZrLcRbciZqWZmqUudke73arn_RMQfXly90g6WkWGiPLkdsaIinFW2whC4-zHdIC45jiB1NLXWR4oC5wzjSg4sNDsG_I2_aCYeXj_WC3H7_tl39XGxufqxX15uFF5qPC8mdnDrDZe1rxXwlmdFeSDCNaKXRrNXeg95VSkEFXnMULaCqpJZewU6JC7I-cZvk9vaQw-DyX5tcsA8HKXfW5TH4Hm2FXNWsNQ1DlDXCrq6xVcxx33rJGj6xvp5Yh-NuwMZP78mufwF9uYnhznbpjwVQXDCY3Xx6JOT0-4hltEMoHvveRUzHYgVwrqUCMV_28T_pPh1znP5qUoGWRnI1A69OKp9TKRnbJzfA7By-ncK3c_gWJvGH5_6fpP-iFvdffqgm</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Keshtkar-Jahromi, Maryam</creator><creator>Anstrom, Kevin J</creator><creator>Barkauskas, Christina</creator><creator>Brown, Samuel M</creator><creator>Daar, Eric S</creator><creator>Fischer, William</creator><creator>Gibbs, Kevin W</creator><creator>Higgs, Elizabeth S</creator><creator>Hughes, Michael D</creator><creator>Jagannathan, Prasanna</creator><creator>LaVange, Lisa</creator><creator>Lindsell, Christopher J</creator><creator>Nayak, Seema U</creator><creator>Paredes, Roger</creator><creator>Parmar, Mahesh</creator><creator>Peltan, Ithan D</creator><creator>Proschan, Michael</creator><creator>Shotwell, Matthew S</creator><creator>Vock, David M</creator><creator>Yokum, Tammy</creator><creator>Adam, Stacey J</creator><general>Cambridge University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4590-5175</orcidid><orcidid>https://orcid.org/0000-0002-3297-2811</orcidid></search><sort><creationdate>2024</creationdate><title>ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic</title><author>Keshtkar-Jahromi, Maryam ; Anstrom, Kevin J ; Barkauskas, Christina ; Brown, Samuel M ; Daar, Eric S ; Fischer, William ; Gibbs, Kevin W ; Higgs, Elizabeth S ; Hughes, Michael D ; Jagannathan, Prasanna ; LaVange, Lisa ; Lindsell, Christopher J ; Nayak, Seema U ; Paredes, Roger ; Parmar, Mahesh ; Peltan, Ithan D ; Proschan, Michael ; Shotwell, Matthew S ; Vock, David M ; Yokum, Tammy ; Adam, Stacey J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-42a4c368249c950c74086c3418d3f4860f6cc16b755171c62e3f1e57464c51b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>ACTIV</topic><topic>Antiviral drugs</topic><topic>clinical trial</topic><topic>Clinical trials</topic><topic>COVID-19</topic><topic>COVID-19 Therapeutic Platform Trials Lessons Learned</topic><topic>COVID-19 vaccines</topic><topic>design</topic><topic>Enrollments</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>lessons</topic><topic>Mortality</topic><topic>Pandemics</topic><topic>Pathogenesis</topic><topic>Patient safety</topic><topic>Review</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Therapeutic targets</topic><topic>Thrombosis</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Keshtkar-Jahromi, Maryam</creatorcontrib><creatorcontrib>Anstrom, Kevin J</creatorcontrib><creatorcontrib>Barkauskas, Christina</creatorcontrib><creatorcontrib>Brown, Samuel M</creatorcontrib><creatorcontrib>Daar, Eric S</creatorcontrib><creatorcontrib>Fischer, William</creatorcontrib><creatorcontrib>Gibbs, Kevin W</creatorcontrib><creatorcontrib>Higgs, Elizabeth S</creatorcontrib><creatorcontrib>Hughes, Michael D</creatorcontrib><creatorcontrib>Jagannathan, Prasanna</creatorcontrib><creatorcontrib>LaVange, Lisa</creatorcontrib><creatorcontrib>Lindsell, Christopher J</creatorcontrib><creatorcontrib>Nayak, Seema U</creatorcontrib><creatorcontrib>Paredes, Roger</creatorcontrib><creatorcontrib>Parmar, Mahesh</creatorcontrib><creatorcontrib>Peltan, Ithan D</creatorcontrib><creatorcontrib>Proschan, Michael</creatorcontrib><creatorcontrib>Shotwell, Matthew S</creatorcontrib><creatorcontrib>Vock, David M</creatorcontrib><creatorcontrib>Yokum, Tammy</creatorcontrib><creatorcontrib>Adam, Stacey J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Journal of clinical and translational science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Keshtkar-Jahromi, Maryam</au><au>Anstrom, Kevin J</au><au>Barkauskas, Christina</au><au>Brown, Samuel M</au><au>Daar, Eric S</au><au>Fischer, William</au><au>Gibbs, Kevin W</au><au>Higgs, Elizabeth S</au><au>Hughes, Michael D</au><au>Jagannathan, Prasanna</au><au>LaVange, Lisa</au><au>Lindsell, Christopher J</au><au>Nayak, Seema U</au><au>Paredes, Roger</au><au>Parmar, Mahesh</au><au>Peltan, Ithan D</au><au>Proschan, Michael</au><au>Shotwell, Matthew S</au><au>Vock, David M</au><au>Yokum, Tammy</au><au>Adam, Stacey J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic</atitle><jtitle>Journal of clinical and translational science</jtitle><addtitle>J Clin Transl Sci</addtitle><date>2024</date><risdate>2024</risdate><volume>8</volume><issue>1</issue><spage>e151</spage><pages>e151-</pages><artnum>e151</artnum><issn>2059-8661</issn><eissn>2059-8661</eissn><abstract>Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) was initiated by the US government to rapidly develop and test vaccines and therapeutics against COVID-19 in 2020. The ACTIV Therapeutics-Clinical Working Group selected ACTIV trial teams and clinical networks to expeditiously develop and launch master protocols based on therapeutic targets and patient populations. The suite of clinical trials was designed to collectively inform therapeutic care for COVID-19 outpatient, inpatient, and intensive care populations globally. In this report, we highlight challenges, strategies, and solutions around clinical protocol development and regulatory approval to document our experience and propose plans for future similar healthcare emergencies.</abstract><cop>England</cop><pub>Cambridge University Press</pub><pmid>39478775</pmid><doi>10.1017/cts.2024.1</doi><orcidid>https://orcid.org/0000-0002-4590-5175</orcidid><orcidid>https://orcid.org/0000-0002-3297-2811</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2059-8661
ispartof Journal of clinical and translational science, 2024, Vol.8 (1), p.e151, Article e151
issn 2059-8661
2059-8661
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7e2590f8d0ee49e1b99ef50a2cfc40d2
source Open Access: PubMed Central; Cambridge University Press
subjects ACTIV
Antiviral drugs
clinical trial
Clinical trials
COVID-19
COVID-19 Therapeutic Platform Trials Lessons Learned
COVID-19 vaccines
design
Enrollments
Hospitalization
Hospitals
lessons
Mortality
Pandemics
Pathogenesis
Patient safety
Review
Severe acute respiratory syndrome coronavirus 2
Therapeutic targets
Thrombosis
Vaccines
title ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A05%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ACTIV%20trials:%20Lessons%20learned%20in%20trial%20design%20in%20the%20setting%20of%20an%20emergent%20pandemic&rft.jtitle=Journal%20of%20clinical%20and%20translational%20science&rft.au=Keshtkar-Jahromi,%20Maryam&rft.date=2024&rft.volume=8&rft.issue=1&rft.spage=e151&rft.pages=e151-&rft.artnum=e151&rft.issn=2059-8661&rft.eissn=2059-8661&rft_id=info:doi/10.1017/cts.2024.1&rft_dat=%3Cproquest_doaj_%3E3122645132%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-42a4c368249c950c74086c3418d3f4860f6cc16b755171c62e3f1e57464c51b53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3116484255&rft_id=info:pmid/39478775&rfr_iscdi=true